Video

Dr. Yardley on the Utility of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer

Denise Yardley, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor

Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the utility of CDK4/6 inhibitors in metastatic hormone receptor (HR)—positive, HER2-negative breast cancer.

Currently, CDK4/6 inhibitors are a standard first- or second-line treatment for patients with HR—positive, HER2-negative breast cancer, says Yardley.

Initially, there was a learning curve with the use of these agents, particularly for patients who have a high tumor burden or metastases in the liver or lung.

However, studies have demonstrated an improvement in overall response rates, progression-free survival, and overall survival with CDK4/6 inhibitors versus standard chemotherapy, says Yardley.

Moving forward, it will be important to understand resistance mechanisms and identify patients who are likely to respond to CDK4/6 inhibitors versus chemotherapy, concludes Yardley.

Related Videos
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS